22 December 2017 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
1 March 2019 in Mental Health Clinician
With the United States in the midst of an opioid overdose epidemic, efforts to reduce overdose deaths have increased. Expanding access to the opioid antagonist naloxone can combat the epidemic. A pilot project in a psychiatric hospital resulted in the development of a screening tool in the electronic medical record (EMR) to help pharmacists identify adult inpatients at high risk of opioid overdose. Pharmacists can facilitate these patients being discharged with take-home naloxone. The purpose of this project was to optimize the screening tool for nonpsychiatric adult inpatient areas. Prior to implementation, a team of pharmacists familiar with the screening tool and take-home naloxone met with stakeholders to assess need for modification of the tool, determine barriers to implementation, and provide insight into the new service. In addition to expanding the tool into nonpsychiatric areas, a morphine-equivalents calculator was developed to identify patients receiving at least 100 mg of morphine equivalents per day to capture an additional at-risk population. Four short educational videos were developed to provide training to pharmacists. Initial performance of the screening tool was evaluated in general medicine patients over a 5-day period. Out of 44 admissions, 8 (18.2%) screened positive. The majority of those patients (5/8, 62.5%) screened positive for morphine equivalents greater than 100 mg. Anecdotally, the educational videos have been well received by pharmacy staff. Opioid overdose risk factors can be applied to nonpsychiatric inpatients for screening purposes in the EMR. Educational videos can be used to disseminate information to pharmacists on take-home naloxone and opioid overdose.
6 April 2026 in SSRN Electronic Journal
Racial disparities in emergency department (ED) use among patients with schizophrenia may reflect differences in treatment continuity after antipsychotic initiation. We examined whether antipsychotic adherence mediated the association between race and ED use and whether mediation differed by antipsychotic class and route of administration. Using South Carolina Medicaid claims from 2004 to 2019, we identified 1,666 adults with schizophrenia or schizoaffective disorder initiating antipsychotic treatment. Adherence was measured as proportion of days covered (PDC) during the first 6 months after treatment initiation. The outcome was any ED visit in the subsequent 6 months. Causal mediation analysis was conducted overall and by antipsychotic subgroup. Black beneficiaries had higher ED use than White beneficiaries (33% vs. 27%, p = 0.03) and lower adherence (mean PDC 0.45 vs. 0.55, p < 0.001). In unadjusted analyses, adherence mediated 23% of the association between race and ED use (95% CI 8%-94%, p = 0.03). After covariate adjustment, adherence mediated 25% of the association (95% CI 10%-95%, p = 0.006). Significant mediation was observed among oral antipsychotic users (28%, p = 0.02), second-generation antipsychotic users (29%, p = 0.008), and most prominently in oral second-generation antipsychotic users (30%, p = 0.006). No significant mediation was observed among first-generation antipsychotic or long-acting injectable users. Antipsychotic adherence explained a significant proportion of racial differences in ED use, particularly among oral second-generation antipsychotic users. These findings suggest that adherence is one pathway contributing to racial disparities in acute psychiatric care.
4 May 2026 in SSRN Electronic Journal
BackgroundSchizophrenia is a chronic mental disorder that requires lifelong treatment. Medication nonadherence contributes to poor medical outcomes; the ability to predict a patient’s adherence trajectory cannot be understated in forestalling the negative effects of nonadherence. This study aimed to identify antipsychotic adherence latent classes among patients diagnosed with schizophrenia or schizoaffective disorder and evaluate predictors of adherence latent classes. Healthcare utilization, including hospitalizations and emergency department visits across adherence trajectories, was also evaluated.MethodsThis study utilized South Carolina Medicaid claims for beneficiaries diagnosed with schizophrenia or schizoaffective disorder from 2014 to 2020 using a latent class mixture modeling framework. This consists of two submodels: a membership model that categorizes patients into adherence classes and a longitudinal model that characterizes adherence trajectories over time within each adherence class.ResultsA total of 2,870 eligible patients were included in the study, with 1,707 males and 1,163 females. Four distinct adherence trajectories were identified: most adherent (56% of the population), early drop-off (12%), initial adherence followed by an increase (8%), least adherent (24%). The impact of predictors and frequency of healthcare utilization outcomes varied across classes. Time consistently demonstrated a significant impact on trajectory shapes.ConclusionFour distinct trajectories for adherence were identified among South Carolina’s Medicaid beneficiaries. Significant patient characteristics that determined class memberships and adherence trajectories varied across classes.